Gene Expression and Isoform Variation Analysis using Affymetrix Exon Arrays by Bemmo, Amandine et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
BMC Genomics
Open Access Methodology article
Gene Expression and Isoform Variation Analysis using Affymetrix 
Exon Arrays
Amandine Bemmo†1,3, David Benovoy†2,3, Tony Kwan2,3, Daniel J Gaffney2,3, 
Roderick V Jensen4 and Jacek Majewski*2,3
Address: 1Universite de Montreal, Montreal, QC, Canada, 2Department of Human Genetics, McGill University, Montreal, QC, Canada, 3McGill 
University and Genome Quebec Innovation Center, Montreal, QC, Canada and 4Department of Biological Sciences, Virginia Tech, Blacksburg, 
Virginia, USA
Email: Amandine Bemmo - amandine.bemmo@umontreal.ca; David Benovoy - davidbenovoy@gmail.com; 
Tony Kwan - tony.kwan@mail.mcgill.ca; Daniel J Gaffney - daniel.gaffney@mcgill.ca; Roderick V Jensen - rvjensen@vt.edu; 
Jacek Majewski* - jacek.majewski@mcgill.ca
* Corresponding author    †Equal contributors
Abstract
Background: Alternative splicing and isoform level expression profiling is an emerging field of interest within
genomics. Splicing sensitive microarrays, with probes targeted to individual exons or exon-junctions, are
becoming increasingly popular as a tool capable of both expression profiling and finer scale isoform detection.
Despite their intuitive appeal, relatively little is known about the performance of such tools, particularly in
comparison with more traditional 3' targeted microarrays. Here, we use the well studied Microarray Quality
Control (MAQC) dataset to benchmark the Affymetrix Exon Array, and compare it to two other popular
platforms: Illumina, and Affymetrix U133.
Results: We show that at the gene expression level, the Exon Array performs comparably with the two 3'
targeted platforms. However, the interplatform correlation of the results is slightly lower than between the two
3' arrays. We show that some of the discrepancies stem from the RNA amplification protocols, e.g. the Exon
Array is able to detect expression of non-polyadenylated transcripts. More importantly, we show that many other
differences result from the ability of the Exon Array to monitor more detailed isoform-level changes; several
examples illustrate that changes detected by the 3' platforms are actually isoform variations, and that the nature
of these variations can be resolved using Exon Array data. Finally, we show how the Exon Array can be used to
detect alternative isoform differences, such as alternative splicing, transcript termination, and alternative
promoter usage. We discuss the possible pitfalls and false positives resulting from isoform-level analysis.
Conclusion: The Exon Array is a valuable tool that can be used to profile gene expression while providing
important additional information regarding the types of gene isoforms that are expressed and variable. However,
analysis of alternative splicing requires much more hands on effort and visualization of results in order to correctly
interpret the data, and generally results in considerably higher false positive rates than expression analysis. One
of the main sources of error in the MAQC dataset is variation in amplification efficiency across transcripts, most
likely caused by joint effects of elevated GC content in the 5' ends of genes and reduced likelihood of random-
primed first strand synthesis in the 3' ends of genes. These effects are currently not adequately corrected using
existing statistical methods. We outline approaches to reduce such errors by filtering out potentially problematic
data.
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Background
Alternative pre-mRNA splicing is a process that allows for
the production of numerous protein variants from a sin-
gle genomic locus. As researchers are becoming aware of
the importance of splicing and mRNA processing in gen-
erating transcriptomic diversity, isoform-sensitive micro-
arrays are rapidly gaining popularity in gene expression
analysis [1,2]. In particular, Affymetrix Exon Arrays are
becoming a standard for both general and isoform-level
expression analysis [3-11]. Briefly, the Exon Array plat-
form relies on 25-mer oligonucleotide probes to target the
individual exons of a gene. The expression level of each
exon can be detected independently, and summarized to
monitor transcript expression levels as well as changes of
individual transcript isoforms. The more universal cover-
age of the "Whole-Transcript" (WT) arrays renders them
an attractive alternative to the traditional 3' biased expres-
sion microarrays.
We have previously successfully used Exon Arrays to dem-
onstrate variation in isoform level expression in human
populations [12] and associate this variation with under-
lying genetic differences [8]. We showed that the Exon
Array is indeed a powerful and flexible tool, allowing for
the detection of changes in splicing, transcript initiation,
and termination. However, analysis of exon-level data is
considerably more complicated than traditional analysis
of gene expression. The complexity of the analysis may
prevent many researchers from using WT arrays and prof-
iting from associated advances in gene expression profil-
ing.
Here, we use the example of a well studied system to out-
line the analysis and present results of a typical Exon Array
experiment. We use the brain and reference human mRNA
samples previously studied by the MicroArray Quality
Control (MAQC) consortium [13,14]. These commer-
cially available samples provide a high quality reference
dataset for comparing microarray results across various
platforms and laboratories. The human brain has very dis-
tinct gene expression signatures, and the comparison with
the reference (combined) tissue pool results in detection
of numerous genes with differential expression levels. The
original MAQC study relied on these samples to demon-
strate high concordance between various microarray plat-
forms. Incidentally, the human brain is also rich in
specific isoforms, and constitutes a highly suitable system
for assessing the performance of the Exon Array as both an
expression and isoform-sensitive platform.
Results
Variability across labs
Five technical replicates of brain and reference were
hybridized in two independent labs: McGill University
(MU) and Virginia Tech (VT), for a total of 20 samples.
Principal component analysis, which is a commonly used
method to visualize sources of variability in the data, is
shown in Figure 1. Our experience with Exon Arrays indi-
cates that in general the ribosomal RNA reduction step is
the most inconsistent part of the protocol and is likely to
be a major contributor to the differences across labs.
Variability in hybridization intensities, background noise,
and random errors across labs may contribute to differ-
ences in final conclusions resulting from microarray anal-
yses. In the case of the MAQC data, the final goal was to
quantify differences in gene expression levels between the
human brain and reference tissues. A relevant metric of
such expression difference is the fold change (FC), calcu-
lated as FC = Expression(Brain)/Expression(Reference). In
Figure 2, we show a correlation plot comparing the calcu-
lated fold changes in genes expression between the two
labs. Despite the inter-lab variability in expression levels
shown in the PCA plots, the final results (fold changes)
are highly consistent for the two labs, with a correlation
coefficient of greater than 0.97.
Variability across summarization methods
The aim of the summarization step in microarray analysis
is generally to combine signals from multiple probes,
which target the same expression unit, into a single
expression index. Most of the popular methods strive for
robustness against outlier probes (e.g. cross hybridizing,
saturated, or non-responsive probes). We used our fold
change results to compare two commonly used summari-
zation methods: PLIER and RMA. We noted that RMA
does result in a slight compression of fold changes, as has
been observed in prior studies using other microarray
platforms [13]. However, we find that the correlation of
fold changes obtained from the two approaches is very
high (r = 0.99).
Variability across platforms
The original MAQC studies demonstrated that microarray
results are highly consistent across different platforms
[13]. In Figure 3, we compare the performance of the Exon
Array in determining gene expression levels with two
other popular platforms previously used by MAQC: Illu-
mina Bead Array and Affymetrix U133 Gene Chip. In
order to facilitate comparison across labs as well as plat-
forms, we selected a number of genes which are reliably
annotated and targeted by a common set of probesets (see
Methods).
For the Exon Arrays, the fold changes were calculated by
combining the results from the two labs (MU and VT). For
the sake of consistency in the comparison, two test sites
were chosen at random and combined for each platform
within the MAQC dataset. We find that the 3' targeted
platforms, Illumina Human-6 BeadChip and AffymetrixBMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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U133, produce the most consistent results (R = 0.92). This
is not surprising, since the probe selection regions for the
two platforms largely coincide, and the amplification pro-
tocols are poly-A primed and biased towards the 3' ends
of genes. The correlation with the Exon Array is slightly
lower: R = 0.89 for U133 and 0.85 for Illumina. It has
been previously shown [15-17], that the Exon Arrays are
effective tools for gene expression profiling. Therefore, it
is of interest, to examine the main sources of differences
between the Exon Arrays and other platforms. Thus, in the
analysis below we will concentrate on the genes whose
predicted expression patterns are not consistent across
platforms. In particular, the Exon Array is able to distin-
guish between specific isoforms of a given genomic locus,
whereas the Illumina and Affymetrix U133 platforms gen-
erally target only a single isoform.
PCA plots at the probe set level show two main sources of variation among the 20 samples Figure 1
PCA plots at the probe set level show two main sources of variation among the 20 samples. The first principal 
component explains 65% of the variance and corresponds, as expected, to the biological source of the sample: brain (B) vs. ref-
erence (R). The second principal component explains 20% of the variance and corresponds to the "lab effect" between VT 
(blue), and McGill (red) – that is, it illustrates the technical variability across labs.BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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Alternative Isoform Detection
It has previously been pointed out that some discordant
results in the original MAQC [13] study were caused by
differential isoform expression, and differences in probe
placement across platforms. One particular discordant
gene, ELAVL1, was suspected to express two alternative
isoforms, differing in the 3' UTR region. In Figure 4, we
use the example of ELAVL1 to illustrate the advantages of
using the Exon Array for profiling individual isoforms.
It is clear that although the Exon Array does not report the
entire gene as differentially expressed, individual
probesets within the gene reach high statistical signifi-
cance levels (p < 10-9). More interestingly, the gene
appears to be composed of two "blocks", with the first
block on the 3' end showing elevated expression in the
brain, while the second block has elevated expression in
the reference sample. In order to understand the more
precise nature of this isoform change, it is advantageous to
Comparison of log2(FC) detected between the biological samples for the two labs Figure 2
Comparison of log2(FC) detected between the biological samples for the two labs. Despite significant variation in 
expression measure across test sites, the fold change estimates are highly correlated.
n = 17665, r = 0.9736796
MU
V
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visualize this data in the context of known gene annota-
tion, EST, and mRNA data. Generally, our lab uses the cus-
tom track feature of the UCSC genome browser [18], in
order to export our own information and combine it with
publicly available data (Figure 5).
In Additional file 1, we present other examples of discord-
ance between the platforms, further illustrating the value
of additional information present on the Exon Array in
profiling both "whole transcript" and "isoform-level"
changes.
Differences in Amplification and Labelling Protocols
The four most discordant genes between the 3' arrays and
the WT array (see Figure 3) are histone genes: HIST1H3B,
HIST1H1B, HIST1H3C, HIST1H3I, all of which are part of
Correlation of fold changes between Affymetrix U133, Illumina, and the Affymetrix Exon Array Figure 3
Correlation of fold changes between Affymetrix U133, Illumina, and the Affymetrix Exon Array. Fold changes 
(log2 transformed) between brain and reference expression levels for 8391 genes common to all three platforms: A) Illumina 
vs. U133. B) Exon Array vs. U133, C) Exon Array vs. Illumina. The arrow points to the highly discordant detection of 4 histone 
genes: HIST1H3B, HIST1H1B, HIST1H3C, HIST1H3I.
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the histone gene cluster on chromosome 6p21.3. The
Exon Array identifies those RNAs as over 50 fold less
abundant in the brain than in the reference sample, while
the 3' targeted platforms register no expression differences
and very low overall expression levels. It has been shown
that most histone genes lack a poly-A tail [19] and that the
stability of such non-adenylated transcripts varies greatly
with intracellular conditions such as those present in
brain tissues [20]. Both Illumina and the Affymetrix U133
arrays use 3', poly-T primed RNA amplification protocols
and do not detect histone gene expression. In contrast, the
Exon Array uses WT random primed amplification, which
does not necessitate the presence of a poly-A tail. The dif-
ference of histone RNA abundance is the most striking
example of a result that is specifically detected by the Exon
Array, but not the other platforms. However, there are
many other such differences within the dataset (see Addi-
tional file 1).
Exon array analysis of the ELAVL1 gene expression differences between brain and reference tissues Figure 4
Exon array analysis of the ELAVL1 gene expression differences between brain and reference tissues. The horizon-
tal scale corresponds to each probeset within the gene from the 3' to 5' ends. The height of the blue bars indicates the log2(fold 
change) in expression between the samples. The red line indicates statistical significance, -log10(p-value).BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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Using the Exon Array to Profile Alternative Isoforms
One of the biggest challenges in profiling alternative iso-
forms using Exon Arrays is the deconvolution of mRNA
processing and transcription. A simple comparison of
probeset intensities across samples is not sufficient; if an
exon belongs to a transcript that is differentially
expressed, the examination of a single exon out of its
genomic context will lead to an incorrect conclusion. A
very simple and intuitive solution to this problem is the
use of the Splicing Index (SI), which is calculated by divid-
ing the probe set intensity by the metaprobeset intensity
(i.e. exon expression/gene expression), after the addition
of a stabilization constant to both the probeset and meta-
probeset scores [21]. This simple procedure normalizes
the expression level of each exon and accounts for any
possible gene expression differences between samples.
However, we find that the splicing index has some unde-
sirable statistical properties (arising from large errors in
Visualization of expression patterns of ELAVL1 gene Figure 5
Visualization of expression patterns of ELAVL1 gene. The top two custom tracks display the Exon Array information 
from Figure 4: statistical significance and fold change. Note that the two probeset "blocks" correspond to the two isoforms of 
the gene. The long 3'UTR isoform is predominantly expressed in the brain, whereas the short isoform is more abundant in the 
reference tissues.BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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the estimates in both the numerator and the denomina-
tor) as well as being prone to methodological artefacts
(see below), and should be used with caution. Thus, we
have also used a simpler, but more labour intensive
method, of carrying out the entire analysis at the probeset
level, and relying on visualization and manual curation of
the results in order to distinguish splicing and expression
differences between samples. While more robust statisti-
cal approaches are being developed, we strongly advocate
visualization of results in the context of genome annota-
tion and EST evidence in order to filter out false positive
signals. We have relied on custom scripts and modifica-
tions of the UCSC and ENSEMBL genome browsers, but
increasingly useful and user-friendly commercial packages
for the Exon Arrays are available (e.g. Partek Genomics
Suite, Biotique XRay) along with academic BioConductor
packages [22-24]. Below, we describe in more detail two
approaches to alternative isoform detection. For the case
of simplicity, only the core (most confident) subset of
Exon Array probesets was considered in this analysis.
Probe set level analysis
At this level of the analysis, each probeset (roughly corre-
sponding to an exon) is used as a unit of expression,
instead of a meta probeset (a transcript) as is done in
more traditional gene expression analysis. With appropri-
ate statistical significance cut-offs (e.g. a Benjamini-Hoch-
berg [25] False Discovery Rate correction), it is generally
possible to select a highly confident set of probesets
exhibiting significantly altered expression. However, it is
not immediately possible to classify the "hits" as results of
alternative isoform expression (e.g. alternative splicing),
differential gene expression, or both. The easiest way of
factoring out of gene expression is to consider only the
genes whose expression does not change across samples
or treatments. That is, we can select probesets that are sta-
tistically significant, but which belong to genes whose
meta-probe set expression does not appear to be signifi-
cantly altered (nominal p > 0.05). For the MAQC samples,
we generated a list of the top 100 such genes. The list and
links to the UCSC browser are provided in the Additional
file 2. The top candidates show evidence for differential
promoter usage, polyadenylation, and alternative splic-
ing. A few examples appear to be annotation errors, where
the Affymetrix annotation combines two distinct genes
into a single transcript cluster. In general, we advocate RT-
PCR based validation of alternative isoforms. However,
cross validation with existing information is also
extremely useful. Extensive EST and mRNA based infor-
mation on tissue specific splicing is available from many
sources, e.g. from the ASAPII [26] or Hollywood [27].
Most of the source data can be viewed directly in the
UCSC genome browser by displaying the mRNA, spliced
EST, or AltEvents tracks.
Splicing Index (SI) analysis
SI is calculated by dividing the probe set intensity by the
metaprobeset intensity. This simple procedure normalizes
the expression level of each exon and should account for
any possible gene expression differences between sam-
ples. An example of a successful use of SI analysis is illus-
trated in Figure 6A. Intuitively, the splicing index may be
viewed as an approximate fractional inclusion level of a
probeset within a transcript. However, we find many sta-
tistical and methodological problems arising from the use
of the SI metric. Specifically, comparing SI values across
samples makes the assumption that all probesets within a
gene have comparable response (linear or log-linear) to
changes in RNA levels. This assumption is generally vio-
lated, and hence SI comparisons result in high false posi-
tive rates. The most severe non-linearities in response are
exhibited by probesets that are expressed close to the
background levels, and probesets within highly expressed
genes whose detection range is saturated. One of the most
common methodological artefacts is illustrated in Figure
6B; probesets that are close to the 3' ends of genes are not
amplified as efficiently as interior probesets while
probesets close to the 5' end have elevated GC content
and reduced specificity (see below). In addition, probesets
that belong to skipped exons, which are included at low
levels in both samples – i.e. these are actually alternatively
spliced exons, but are NOT differentially spliced across
samples. It should be noted that such artefacts are not lim-
ited to the use of the splicing index, and also applied to
other commonly employed methods that attempt to cor-
rect for expression differences, such as the two-way
ANOVA method implemented by Partek and Biotique
XRay software. Some of the arising problems may be
avoided by various filtering approaches; e.g. removing
probesets with extremely high or low SI values, or
probesets with extremely low coefficients of variation
(possibly saturated). A more detailed discussion of these
effects is presented at the Affymetrix website [21] and
methods are being developed to enable these filtering cri-
teria in an automated fashion [28]. Such approaches are
likely to reduce false positive rates, at a cost of a reduced
coverage of the genome. In Additional file 3 we present
the top 100 candidates resulting from the SI analysis of
the MAQC data, after filtering out all probesets expressed
below background (average detection above background
[DABG] p-value > 0.05).
Edge Bias Effect
In the course of the splicing index analysis described
above, we noted an excess of "hits" occurring in the 3' and
5' regions of transcripts. We hypothesized that this effect
could arise partly due to a bias during the first strand syn-
thesis in the random primed amplification step used in
exon array processing. Briefly, first strand synthesis pro-
ceeds from the 3' end to the 5' end of each transcript, ini-BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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tiating at random points along the mRNA molecule. Each
probeset in the interior of the mRNA is likely to be repre-
sented by multiple randomly primed initiation events.
However, probesets towards the 3' end of the mRNA have
a lower chance of coverage – simply because the molecule
ends and priming cannot occur at any point downstream
of the 3' end. In order to test this hypothesis and quantify
the possible biases, we calculated mean probeset hybridi-
zation intensities as a function of distance from the 3' and
5' edge of the targeted mRNA molecule. The results are
shown in Figure 7. It is evident that the intensity of the sig-
nal increases depending on the distance from the polyA
site. No such effect is seen for the distance from transcrip-
tion start site (5'). This effect is further illustrated in Figure
8, which shows that Exon Array gene expression levels are
highly correlated with gene length, i.e. short genes appear
to be expressed at lower levels than long genes, which is
most likely caused by relatively lower efficiency in ampli-
fying short mRNA molecules.
We also noted that the ability of the Exon Array to detect
hybridization above background noise levels is not uni-
form across transcripts. The Exon Array allows the calcula-
tion of DABG p-values, which estimate the probability
that signal originates from the background noise distribu-
tion, rather than true gene expression. In general,
probesets with DABG values lower than 0.05 can be
accepted to represent true signal. Average DABG values are
least significant at both 3' and 5' ends of the gene. The
reduction at the 3' end results from the reduced signal
intensity levels described above. The reduction at the 5'
end is more puzzling, in the absence of a corresponding
reduction in signal. We hypothesize that the 5' effect is
most likely the result of an elevated GC content of probes
Examples of Candidates from Splicing Index Analysis Figure 6
Examples of Candidates from Splicing Index Analysis. Top panels show the p-values (dotted line) and fold-changes 
(blue bars) for the expression of individual probesets. The centre panels show the values normalized for overall difference in 
gene expression (SI). Bottom panels show the raw hybridization levels of each probeset. A) MADD – successful use of the 
splicing index. In this example, in the presence of an overall 3-fold gene expression difference between the samples, the SI fac-
tors out the expression difference and indicates three alternatively spliced probesets – 3329761, 3329771, and 33291783 – all 
of which have strong supporting RefSeq annotation evidence for alternative splicing. B) TYMS – a typical false positive, where 
differences in probe response levels close to the edges of the transcript suggest alternative isoform usage. Such results are 
often erroneous, resulting from non-uniform response of individual probesets to large (in this case ~20 fold) changes in gene 
expression. Note the elevated signal intensity (bottom panel) at the 5' end of the gene, suggesting saturation, and a reduced 
intensity at the 3' terminus, possibly to reduced amplification efficiency.
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Edge bias Figure 7
Edge bias. This figure illustrates variation of hybridization intensity across transcripts. For each probeset expressed above 
background levels, we determined the average hybridization intensity as a function of distance from the 5' and 3' ends of the 
mRNA molecule. Top panels show the average signal intensity as a function of probeset distance from the 5' and 3' ends of 
transcripts. A significant decrease in signal strength is seen at the 3' end, while a slight increase occurs at the 5' end. Bottom 
panels illustrate the ability of the array to detect the hybridization signal above background levels. Mean DABG values decrease 
at both 5' and 3' extremities of genes. The 3' effect results directly from the reduction in hybridization intensity. The 5' effect is 
most likely the result of increased GC content of the 5' probes located close to unmethylated gene promoters and CpG 
islands. Both effects cause false positive results in Splicing Index and Splicing ANOVA analyses in the presence of changes in 
expression of the whole transcript. Only genes with detectable expression (average DABG p-value < 0.05) and total mRNA 
length greater than 1000 nucleotides were included in this analysis. The values were calculated as log-averages of core 
probeset intensity across all samples. Each point on the plot corresponds to all probeset ending within a bin of length 10 bp, at 
the indicated distance from mRNA termini.
l
o
g
2
(
s
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
)
-
l
o
g
1
0
(
D
A
B
G
)
Distance from the 3’ end Distance from the 5’ end 3’ 5’
3’ 5’BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
Page 11 of 15
(page number not for citation purposes)
located close to promoter regions which are generally
unmethylated, GC-rich and enriched in CpG islands
[29,30]. In fact the DABG trend at the 5' end inversely mir-
rors the GC content of the probesets (data not shown).
In effect, probesets that are close to the ends of a gene are
likely to exhibit response properties different from the rest
of the transcript, and hence produce excess false positive
results. Such artefacts are difficult to correct using filtering
methods, because the terminal probesets in question are
usually detected as expressed above background, but do
not respond to expression changes as well as those in the
remainder of the gene. In the future, it may be possible to
correct for the edge bias by improving the amplification
protocol, or computational adjustments. However, at this
point interesting Exon Array results in the 3' and 5' ends
of genes, particularly those obtained from SI or two-way
ANOVA analyses, should be treated with extra caution.
Discussion
The recognition of alternative splicing and alternative iso-
form expression as an important component in gene
Exon Array average gene expression index as a function of transcript (mRNA) length Figure 8
Exon Array average gene expression index as a function of transcript (mRNA) length. There is a highly significant 
positive correlation of expression and length (R = 0.18, p < 10-20). This effect is most likely an artefact of the edge bias illus-
trated in Figure 7; short transcripts have a lower overall efficiency of first strand synthesis and appear to be expressed at lower 
levels. The effect is not observed in the 3' amplified U133 (R = 0.05) and Illumina (R = -0.03) results.
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expression analysis has prompted the introduction of iso-
form sensitive microarray platforms. By targeting individ-
ual exons, exon junctions, and annotated isoform
variants, such platforms possess the ability to profile not
only the expression levels of the entire transcript, but also
variations in the types of expressed isoforms. The Affyme-
trix Exon Array 1.0 ST is one of such commercially availa-
ble platforms. To date, it has been shown that the Exon
Array produces gene expression measurements that are
comparable with the previous generation 3' targeted
arrays. However, little is known about the in-depth level
of similarities and particularly differences among WT and
3' based technologies.
This comparison utilizes the well studied brain and refer-
ence samples previously used in the MAQC study to deter-
mine sources of variability in profiling gene expression
using microarrays. These samples are particularly valuable
for the purposes of benchmarking the performance of the
Exon Array for two reasons: 1) they allow easy compari-
son of gene expression level measurements with other
platforms that have already been tested, and 2) they allow
detection of alternative splicing and isoform difference,
since neural tissues are known to be particularly prone to
alternative splicing.
Our first conclusions concern the utility of the Exon Array
as an expression profiling tool. We note that although the
Exon Array results are very consistent with 3' profiling
methods, the level of agreement between the Exon Array
and 3' targeted platforms (Illumina and Affymetrix U133)
is slightly lower than the agreement between the 3' plat-
forms. There are at least two reasons for the decreased con-
cordance.
Firstly, the Exon Array uses a whole transcript, randomly
primed amplification protocol, while the two other plat-
forms rely on polyA tail priming. As a result, the two
approaches amplify a slightly different RNA pool. This is
illustrated very well by the example of several histone
genes (known to lack a polyA tail), which the Exon Array
indicates are expressed at a much lower level in the brain
than in the reference, while the other two platforms indi-
cate a uniform very low level of expression of histone tran-
scripts. As far as we know, differences in expression of
histone genes across tissues and treatments have not pre-
viously been detected by microarray analysis, and this
result is only detectable using the WT approach.
Secondly, many of the outliers in the correlation plot (Fig-
ure 3) are due to the presence of real variations in the
expression of specific isoforms. This is illustrated using a
previously noted example of the ELAVL1  gene, which
showed discordance across platforms in the original
MAQC study, as well as in additional new examples
(Additional file 1). The detected expression differences of
transcript variants may have important biological signifi-
cance. For example the longer 3' UTR in the dominant
ELAVL1 transcript in brain has a different set of putative
micro RNA binding sites than the shorter 3' UTR in the ref-
erence RNA.
It should also be noted that discordant results will often
be obtained because of differences in the annotation pro-
vided by microarray manufacturers. We circumvented
most of such problems here by re-mapping the probes
and selecting only a subset of genes that we were confi-
dent were correctly targeted by all three platforms, but
researchers should keep in mind that the annotations and
gene assignments provided by manufacturers contain
numerous errors [31]. In the case of the Exon Array, we
found that the most common annotation error resulted
from joining together distinct transcripts into single meta-
probesets, particularly in the case of transcripts that par-
tially overlap. Thus, we recommend that lists of candi-
dates from individual experiments should be carefully
curated.
We also outline how the Exon Array can be used to detect
alternative splicing and alternative mRNA processing
events. Although our analysis methods are not in them-
selves novel, and most of them have been briefly
described elsewhere [12,21], our goal is to convey to the
potential users their intuitive appeal and potential pitfalls.
The most challenging step remains the decoupling of
whole transcript expression, and individual probeset
inclusion. The simplest solution to this problem is to con-
sider only the genes that do not change overall expression
levels, but contain probesets that exhibit individual varia-
tions. Although this approach produces a highly confi-
dent set of alternative events, it can result in a huge
reduction of the dataset, particularly in case of compari-
sons across samples with highly heterogeneous gene
expression levels. In the case of MAQC dataset, which has
been chosen for the exact reason of it's extreme gene
expression variability, imposing the restriction of expres-
sion fold change of less than 2 reduces the total number
of genes considered by 31% (from 17665 to 12198).
A more inclusive approach is to attempt to correct for gene
expression differences that may occur concurrently to
splicing differences. We discuss two such approaches: 1)
the splicing index, which compares probeset inclusion
across samples after normalizing by gene expression lev-
els, and 2) two-way ANOVA, where the interaction term
between sample type and probeset can be used to indicate
differential inclusion of probesets within transcripts. Both
approaches suffer from similar systematic biases; they
assume a uniform (linear or log-linear) response of each
probeset within a meta-probeset. This assumption is vio-BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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lated in many cases, particularly for probesets that hybrid-
ize at very high levels (saturated response) or probesets
with hybridization levels close to background (poorly or
non-responsive). As a result, in the presence of significant
gene expression changes, such analyses predominantly
indicate three types of events: dead probesets, saturated
probesets, and probesets that may be predominantly
skipped (alternative), but not necessarily differentially
included across samples. All three types of results consti-
tute false positives, and contribute to the high false posi-
tive rates of such analyses.
We also point out two major systematic errors. First, we
show that hybridization intensity decreases for probesets
close to the 3' mRNA ends, an effect that we believe stems
from the random amplification protocol used by the Exon
Array. We argue that this is not an annotation artefact, but
most likely results from the end of template and reduced
random priming potential in the first strand synthesis step
amplification. As a result, 3' regions of genes are detected
at near background levels, and frequently indicate alterna-
tive isoform presence using the SI or ANOVA approaches.
A similar problem exists at the 5' end of transcripts, where
we hypothesize that the reduction in DABG levels is
caused by the elevated GC content of the probesets. These
problems are particularly troubling, since many cases of
alternative polyadenylation and promoter usage may in
fact be associated with changes in transcript expression.
This may be due to different promoter strength, or micro-
RNA mediated regulation in 3' UTR (as is likely to be the
case in the ELAVL1 example shown in Figures 4 and 5).
Such real and potentially extremely interesting cases may
be difficult to distinguish from differences in probe
hybridization potential.
Many of the above systematic errors can be avoided by fil-
tering out potentially troublesome subsets of the data:
probesets with extremely low variability (saturated),
probeset with low inclusion levels (close to background),
and genes with extremely high differences in expression
levels across samples. However, such filtering decreases
the false positive rates at the cost of reduced genomic cov-
erage.
In our earlier studies, we have also pointed out that in
many experimental designs, particularly when samples
originate from different genetic backgrounds (e.g. differ-
ent individuals), the presence of sequence variants within
probe target sequences may be a very significant source of
errors [8,12]. This effect can be especially prominent in
eQTL association studies, where we have shown that it can
be responsible for a false positive rate > 80% in alternative
splicing analysis [32]. Thus, unless all tested samples are
isogenic, we highly recommend additionally "masking"
all probes containing known polymorphisms before per-
forming the analysis.
Conclusion
In summary, the WT profiling provides a wealth of valua-
ble information, which is either not available or misrepre-
sented in traditional 3' gene expression arrays. However,
it should be noted that the isoform-level analysis of Exon
Arrays is significantly more complicated, suffers from
higher false positive rates, and requires more manual
intervention than traditional gene expression analysis. We
strongly advocate visualization of candidate isoform
changes in the context of available genome annotation as
a means to both reduce false positive rates and interpret
the nature of detected variants.
Methods
Exon Array Hybridization
The Universal Human Reference RNA (catalogue no.
740000) and Human Brain Reference RNA (catalogue no.
6050) were obtained from Stratagene and Ambion,
respectively. The RNA quality was assessed using RNA
6000 NanoChips with the Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, USA). Five technical replicates of each
sample were hybridized independently at two test sites:
McGill University and Genome Quebec Innovation Cen-
tre (Montreal, Quebec, Canada) and Virginia Tech
(Blacksburg, Virginia, USA). Biotin-labelled target for the
microarray experiment were prepared using 1 μg of total
RNA. The RNA was subjected to an rRNA removal proce-
dure with the RiboMinus Human/Mouse Transcriptome
Isolation Kit (Invitrogen) and cDNA was synthesized
using the GeneChip® WT (Whole Transcript) Sense Target
Labelling and Control Reagents kit as described by the
manufacturer (Affymetrix). The sense cDNA was then
fragmented by UDG (uracil DNA glycosylase) and APE 1
(apurinic/apyrimidic endonuclease 1) and biotin-labelled
with TdT (terminal deoxynucleotidyl transferase) using
the GeneChip®  WT Terminal labelling kit (Affymetrix,
Santa Clara, USA). Hybridization was performed using 5
micrograms of biotinylated target, which was incubated
with the GeneChip® Human Exon 1.0 ST array (Affyme-
trix) at 45°C for 16–20 hours. Following hybridization,
non-specifically bound material was removed by washing
and detection of specifically bound target was performed
using the GeneChip® Hybridization, Wash and Stain kit,
and the GeneChip® Fluidics Station 450 (Affymetrix). The
arrays were scanned using the GeneChip® Scanner 3000
7G (Affymetrix) and raw data was extracted from the
scanned images and analyzed with the Affymetrix Power
Tools software package (Affymetrix). The microarray data
has been deposited in the Gene Expression Omnibus
Database (GEO: GSE13072).BMC Genomics 2008, 9:529 http://www.biomedcentral.com/1471-2164/9/529
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Data Pre-processing and Analysis
The Affymetrix Power Tools software package (Affymetrix)
was used to quantile normalize the probe fluorescence
intensities and to summarize the probe set (representing
exon expression) and meta-probe set (representing gene
expression) intensities using a probe logarithmic intensity
error model (PLIER, [33]) or robust multichip analysis
(RMA, [34]). The above procedures were carried out sepa-
rately for the two test sites (McGill University and Virginia
Tech). The raw data (.cel files) was downloaded from the
MAQC website for the Illumina and U133 arrays. In order
to keep the number of replicates and test sites consistent
across platforms, we only used two of the MAQC test sites
(a total of 10 technical replicates of each sample). For the
probeset-level analysis and alternative isoform detection,
we only used the most confident subset of core probesets
from the Exon Array.
Probeset and Gene Mapping
To determine a subset of genes common to the three plat-
forms, we used the mapping provided by the MAQC study
[14] to select 12091 probesets common Illumina and
Affymetrix U133 arrays. Subsequently, we used the Exon
Array probeset annotation and retained only the genes
where the Exon Array meta-probeset coordinates con-
tained both the Illumina and U133 probesets. This proce-
dure resulted in 8391 genes with a high confidence
concordant mapping across the three platforms.
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